rs34612342 — MUTYH Y179C

MUTYH Y179C — The Most Common Base Excision Repair Defect

Every cell division exposes DNA to oxidative damage from normal metabolism. One of the most frequent and dangerous lesions is 8-oxoguanine¹¹ 8-oxoguanine
8-oxo-7,8-dihydroguanine (8-oxoG), a mutagenic oxidative DNA lesion that mispairs with adenine during replication, causing G:C to T:A transversion mutations if uncorrected (8-oxoG), which mispairs with adenine during replication. The MUTYH gene encodes a DNA glycosylase that patrols freshly replicated DNA, scanning for adenines that have been incorrectly inserted opposite 8-oxoG and excising them so the base excision repair²² base excision repair
A fundamental DNA repair pathway: a glycosylase removes the damaged or mismatched base, AP endonuclease nicks the backbone, polymerase fills the gap, and ligase seals it (BER) pathway can insert the correct cytosine. Y179C is the single most common pathogenic variant in MUTYH, accounting for approximately 50-55% of all disease-causing MUTYH alleles in Europeans. When both copies of the gene are non-functional — either homozygous Y179C or compound heterozygous with the other common variant G396D — the resulting condition is MUTYH-Associated Polyposis (MAP), with a dramatically elevated colorectal cancer risk.

The Mechanism

The Y179C variant substitutes tyrosine with cysteine at position 179 within the HhH-GPD domain³³ HhH-GPD domain
The helix-hairpin-helix glycopeptidase D domain, a conserved structural motif in DNA glycosylases that directly contacts the DNA substrate and positions the catalytic residues for base excision of the MUTYH protein, a domain directly responsible for DNA binding and catalytic activity. This missense change severely disrupts the enzyme's ability to recognize adenine:8-oxoG mismatches and excise the misincorporated adenine. Functional studies demonstrate that Y179C MUTYH retains less than 2% of normal glycosylase activity — substantially less than the G396D variant, which retains roughly 2-5%. This explains why Y179C homozygotes develop disease earlier and with greater severity than G396D homozygotes.

Without functional MUTYH, adenine:8-oxoG mismatches persist through successive rounds of replication, converting them into permanent G:C to T:A transversion mutations. These transversions accumulate preferentially in the APC tumor suppressor gene⁴⁴ APC tumor suppressor gene
Adenomatous Polyposis Coli, a gatekeeper tumor suppressor whose inactivation initiates the adenoma-carcinoma sequence in colorectal epithelium, inactivating it and initiating the formation of adenomatous polyps — the precursors to colorectal cancer.

MAP follows autosomal recessive inheritance⁵⁵ autosomal recessive inheritance
Both copies of the gene must carry pathogenic variants for the full disease phenotype; carriers of a single mutant copy retain sufficient enzyme activity from the normal allele. Biallelic carriers (homozygous Y179C or compound heterozygous Y179C/G396D) develop tens to hundreds of colorectal adenomas, typically presenting between ages 40 and 55. Heterozygous carriers retain one fully functional MUTYH allele and have near-normal BER capacity.

The Evidence

The landmark 2002 study⁶⁶ landmark 2002 study
Al-Tassan N et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet, 2002 by Al-Tassan and colleagues first identified biallelic MUTYH mutations — including the Y179C variant — in a family with multiple colorectal adenomas carrying a characteristic excess of somatic G:C to T:A transversions in the APC gene. This landmark discovery established a new mechanism for hereditary colorectal cancer: defective base excision repair.

Sieber et al.⁷⁷ Sieber et al.
Sieber OM et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med, 2003 confirmed the association by screening 152 patients with multiple adenomas and 107 with classic familial adenomatous polyposis, demonstrating that biallelic MYH mutations predispose to a recessive polyposis phenotype.

The largest risk quantification comes from a meta-analysis of 20,565 cases and 15,524 controls⁸⁸ meta-analysis of 20,565 cases and 15,524 controls
Theodoratou E et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer, 2010. Biallelic MUTYH carriers had an odds ratio of 28 (95% CI 6.95-115) for colorectal cancer. For monoallelic Y179C carriers specifically, the OR was 1.34 (95% CI 1.01-1.77) — a modest, borderline-significant elevation. Overall monoallelic MUTYH carrier OR was 1.16 (95% CI 1.00-1.34).

Nielsen et al.⁹⁹ Nielsen et al.
Nielsen M et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology, 2009 studied 257 MAP patients and found critical genotype-phenotype differences: Y179C homozygotes presented with CRC at a mean age of 46, compound heterozygotes (Y179C/G396D) at 52, and G396D homozygotes at 58. This confirms that Y179C is the more severe of the two common variants, consistent with its greater loss of glycosylase activity.

Practical Implications

For GG individuals: both copies of MUTYH function normally. Your base excision repair pathway handles oxidative DNA damage effectively at this locus.

For AG (heterozygous carrier) individuals: you carry one non-functional copy of MUTYH. Your remaining functional allele provides adequate DNA repair. The primary considerations are a modest personal CRC risk elevation (OR ~1.3) and the reproductive implications — if your partner also carries a pathogenic MUTYH variant, each child has a 25% chance of developing MAP. Beginning colonoscopy screening at age 40 is appropriate given the carrier status.

For AA (biallelic) individuals: you have MUTYH-Associated Polyposis. ACG guidelines¹⁰¹⁰ ACG guidelines
Syngal S et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 recommend colonoscopy every 1-2 years starting at age 25-30. Annual colonoscopy with polypectomy if adenomas are found. Upper endoscopy for duodenal adenomas should begin at age 30-35. Colectomy may become necessary if polyp burden exceeds what can be managed endoscopically.

Interactions

The most clinically important interaction is with G396D (rs36053993)¹¹¹¹ G396D (rs36053993)
The second most common MUTYH pathogenic variant, accounting for 25-30% of disease alleles in Europeans; it affects the nudix hydrolase domain rather than the HhH-GPD domain, the other common MUTYH pathogenic variant. Compound heterozygosity — carrying one Y179C allele and one G396D allele — produces the full MAP phenotype, functionally equivalent to homozygosity for either variant. This compound heterozygous state is common among MAP patients because the two variants segregate independently and together account for 75-85% of pathogenic MUTYH alleles in Europeans.

If a user is heterozygous at both rs34612342 (Y179C carrier, AG) and rs36053993 (G396D carrier, AG), they are compound heterozygous and should follow the full MAP surveillance protocol — colonoscopy every 1-2 years from age 25-30, upper endoscopy from age 30-35. This compound action is critical because neither individual carrier genotype alone triggers the intensive surveillance recommendation. The compound Y179C/G396D genotype carried a mean CRC diagnosis age of 52 in the Nielsen et al. study, intermediate between Y179C homozygotes (age 46) and G396D homozygotes (age 58).